1. A glyco-engineered anti-HER2 monoclonal antibody (TrasGEX) induces a long-lasting remission in a patient with HER2 overexpressing metastatic colorectal cancer after failure of all available treatment options. Issue 12 (18th September 2015) Authors: Eisner, Florian; Pichler, Martin; Goletz, Steffen; Stoeger, Herbert; Samonigg, Hellmut Journal: Journal of clinical pathology Issue: Volume 68:Issue 12(2015) Page Start: 1044 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗